| pubmed-article:19523819 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19523819 | lifeskim:mentions | umls-concept:C0376601 | lld:lifeskim |
| pubmed-article:19523819 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:19523819 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:19523819 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:19523819 | lifeskim:mentions | umls-concept:C0917728 | lld:lifeskim |
| pubmed-article:19523819 | pubmed:issue | 15 | lld:pubmed |
| pubmed-article:19523819 | pubmed:dateCreated | 2009-7-14 | lld:pubmed |
| pubmed-article:19523819 | pubmed:abstractText | A novel class of tetrahydro-pyrazinopyrimidine-2-carboxamides have been identified as HIV-1 integrase inhibitors. Optimization of the initial lead culminated in the discovery of a series of compounds with high potency on the enzyme and an antiviral cell-based activity equivalent to that showed by Raltegravir, the first in class HIV-1 integrase inhibitor. | lld:pubmed |
| pubmed-article:19523819 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19523819 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19523819 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19523819 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19523819 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19523819 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19523819 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19523819 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19523819 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19523819 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:19523819 | pubmed:author | pubmed-author:RowleyMichael... | lld:pubmed |
| pubmed-article:19523819 | pubmed:author | pubmed-author:JonesPhilipP | lld:pubmed |
| pubmed-article:19523819 | pubmed:author | pubmed-author:FioreFabrizio... | lld:pubmed |
| pubmed-article:19523819 | pubmed:author | pubmed-author:SummaVincenzo... | lld:pubmed |
| pubmed-article:19523819 | pubmed:author | pubmed-author:PetrocchiAles... | lld:pubmed |
| pubmed-article:19523819 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19523819 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:19523819 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:19523819 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19523819 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19523819 | pubmed:pagination | 4245-9 | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:meshHeading | pubmed-meshheading:19523819... | lld:pubmed |
| pubmed-article:19523819 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19523819 | pubmed:articleTitle | N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors. | lld:pubmed |
| pubmed-article:19523819 | pubmed:affiliation | Departments of Medicinal Chemistry and Drug Metabolism IRBM-MRL, Via Pontina, Km 30.600, 00040 Pomezia (RM), Italy. alessia_petrocchi@merck.com | lld:pubmed |
| pubmed-article:19523819 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19523819 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:19523819 | lld:chembl |
